Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Trial ID or NCT#
NCT00186277
Status
NOT RECRUITING
Purpose
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
Official Title
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Eligibility Criteria
Ages Eligible for Study: 18 to 70
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Sandy Srinivas
Medical oncologist,
Urologic specialist,
Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology
View on ClinicalTrials.gov
